Related Experiment Video

Updated: Apr 12, 2026

Individualized Reconstitution of Human Milk Microbiota: A Feasible Approach in Real-World Settings
04:16

Individualized Reconstitution of Human Milk Microbiota: A Feasible Approach in Real-World Settings

Published on: February 7, 2025

1.0K

Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting

Ener Cagri Dinleyici1, Nazan Dalgic2, Sirin Guven3

  • 1Faculty of Medicine, Department of Pediatrics, Pediatric Intensive Care and Infectious Disease Unit, Eskisehir Osmangazi University, Eskisehir, Turkey.

Jornal De Pediatria
|May 20, 2015
PubMed

Insights

Lactobacillus reuteri DSM 17938 significantly reduced diarrhea duration in outpatient children. This probiotic is safe and well-tolerated for treating acute infectious diarrhea in children.

Area of Science:

  • Microbiology
  • Pediatric Gastroenterology
  • Clinical Research

Background:

  • Previous studies demonstrated Lactobacillus (L.) reuteri DSM 17938 efficacy in hospitalized children with acute infectious diarrhea.
  • This study aimed to evaluate L. reuteri DSM 17938 in an outpatient setting for pediatric acute infectious diarrhea.

Purpose of the Study:

  • To assess the efficacy and safety of L. reuteri DSM 17938 in treating acute watery diarrhea in children presenting at outpatient clinics.
  • To compare the duration of diarrhea and recovery rates between children receiving L. reuteri DSM 17938 and those receiving only oral rehydration solution (ORS).

Main Methods:

  • A multicenter, randomized, single-blinded, case-control trial involving 64 children with acute watery diarrhea.
  • Participants received either L. reuteri DSM 17938 (1×10^8 CFU/day for 5 days) plus ORS, or ORS alone.
  • Primary endpoint: duration of diarrhea (hours); Secondary endpoints: daily diarrhea incidence and adverse events.

Main Results:

  • The mean duration of diarrhea was significantly shorter in the L. reuteri group (60.4 hours) compared to the control group (74.3 hours) (p<0.05).
  • A lower percentage of children in the L. reuteri group experienced diarrhea after 48 hours (44.8%) versus the control group (87%) (p<0.01).
  • No adverse effects were associated with L. reuteri administration.

Conclusions:

  • L. reuteri DSM 17938 is an effective treatment for reducing the duration of acute infectious diarrhea in outpatient children.
  • The probiotic demonstrated a favorable safety profile and was well-tolerated in the pediatric population studied.
  • These findings support the use of L. reuteri DSM 17938 as a therapeutic option for pediatric acute infectious diarrhea in outpatient settings.
Abstract

Keywords:
Ambulatory careChildrenCriançasCuidado ambulatorialDiarreiaDiarrheaLactobacillus reuteri DSM 17938ProbioticProbióticos

More Related Videos

Author Spotlight: Methods for Electroporation and Transformation Confirmation in Limosilactobacillus reuteri DSM2001611:04

Author Spotlight: Methods for Electroporation and Transformation Confirmation in Limosilactobacillus reuteri DSM20016

Published on: June 23, 2023

5.3K
Probiotic Studies in Neonatal Mice Using Gavage10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

21.3K

Related Concept Videos

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
559
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
924
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
727
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
389
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid...
59
Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
231